JPMorgan Chase & Co. Lowers Doximity (NYSE:DOCS) Price Target to $28.00

Doximity (NYSE:DOCS) had its price target lowered by investment analysts at JPMorgan Chase & Co. from $33.00 to $28.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 60.38% from the company’s current price.

Other research analysts also recently issued research reports about the stock. KeyCorp downgraded shares of Doximity from an “overweight” rating to a “sector weight” rating in a report on Thursday. Mizuho dropped their price target on Doximity from $34.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday. The Goldman Sachs Group dropped their price target on Doximity from $28.00 to $24.00 and set a “neutral” rating on the stock in a research report on Thursday. Canaccord Genuity Group set a $30.00 price target on Doximity in a research report on Thursday. Finally, Truist Financial reaffirmed a “hold” rating and issued a $19.00 price target (down from $29.00) on shares of Doximity in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat.com, Doximity has an average rating of “Moderate Buy” and a consensus target price of $31.48.

Doximity Trading Down 25.4%

DOCS traded down $5.93 during trading on Thursday, hitting $17.46. The stock had a trading volume of 17,685,978 shares, compared to its average volume of 3,604,347. The stock has a market capitalization of $3.22 billion, a price-to-earnings ratio of 14.64, a PEG ratio of 1.88 and a beta of 1.36. Doximity has a 12 month low of $17.15 and a 12 month high of $76.51. The company has a 50 day simple moving average of $24.27.

Doximity declared that its board has initiated a stock repurchase program on Thursday, February 5th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other news, insider Siddharth Sitaram sold 2,309 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $25.77, for a total transaction of $59,502.93. Following the sale, the insider directly owned 89,396 shares in the company, valued at approximately $2,303,734.92. The trade was a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Scherer Wampler sold 9,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $26.06, for a total value of $234,540.00. Following the sale, the director owned 19,839 shares in the company, valued at approximately $517,004.34. This represents a 31.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 18,055 shares of company stock worth $456,061. 31.30% of the stock is currently owned by company insiders.

Institutional Trading of Doximity

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Doximity by 4.1% in the fourth quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock valued at $588,281,000 after acquiring an additional 518,916 shares during the period. Aubrey Capital Management Ltd bought a new stake in Doximity in the third quarter valued at about $4,572,000. UBS Group AG increased its stake in Doximity by 26.5% in the fourth quarter. UBS Group AG now owns 680,260 shares of the company’s stock valued at $30,122,000 after acquiring an additional 142,408 shares during the period. Blair William & Co. IL increased its stake in Doximity by 1,990.7% in the third quarter. Blair William & Co. IL now owns 362,740 shares of the company’s stock valued at $26,534,000 after acquiring an additional 345,390 shares during the period. Finally, William Blair Investment Management LLC grew its position in Doximity by 11.7% in the third quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company’s stock valued at $426,404,000 after acquiring an additional 609,775 shares during the period. Institutional investors own 87.19% of the company’s stock.

Key Stories Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported adjusted EPS of $0.26, which topped a lower analyst estimate of $0.17, and revenue rose 5.1% year over year to $145.37 million, showing the business is still growing. Doximity Earnings Report
• Positive Sentiment: Management said AI tool adoption and growth in larger customers helped engagement, and the company highlighted record free cash flow and continued AI integration efforts. Doximity Q4 2026 Earnings Call Highlights
• Neutral Sentiment: Wall Street analysts responded by cutting price targets, but most kept neutral-to-positive ratings, suggesting the stock may be viewed as oversold rather than fundamentally broken. Analyst Price Target Updates
• Negative Sentiment: The bigger concern is that Doximity’s fiscal 2027 revenue guidance of $664 million to $676 million came in below the $696 million consensus, pointing to a slower growth outlook than investors wanted. Doximity Q4 2026 Earnings Call Transcript
• Negative Sentiment: First-quarter fiscal 2027 revenue guidance of $151 million to $152 million also missed expectations, reinforcing worries that growth is slowing and AI-related investment is pressuring margins. Doximity plunges on weak guidance
• Negative Sentiment: Additional sentiment pressure came from unusual put buying and a disclosed insider share sale, both of which can signal caution among traders. Insider Trade Disclosure

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.